Products - Multiple sclerosis | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 25 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Ublituximab for treating relapsing multiple sclerosis (TA1025)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2024
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
28 May 2014
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
19 December 2019
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
22 August 2007
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 June 2022
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 June 2021
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 May 2021
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 February 2020
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2019
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 July 2018
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2018
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 August 2014
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 June 2014
Published:
22 January 2014
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 April 2012
Cladribine for treating relapsing multiple sclerosis [ID6263]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 April 2025
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
2 April 2025
Expected publication date:
10 July 2025
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Glatiramer acetate depot for multiple sclerosis [TSID10620]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tolebrutinib for treating relapsing multiple sclerosis [ID6351]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC